再生元 JPM 2025 FINAL for Filing.pdf

1、J.P.Morgan Healthcare ConferenceJ A N U A R Y 1 3,2 0 2 5This non-promotional presentation contains investigational data as well as forward-looking statements;actual results may vary materially.2Strategy&Business UpdateJ.P.M o r g a n H e a l t h c a r e C o n f e r e n c e 2 0 2 5Leonard S.Schleife

2、r,MD,PhD Co-Founder,Board Co-Chair,President&Chief Executive Officer3Note regarding forward-looking statementsThis presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals,Inc.(Regeneron or

3、 the Company),and actual events or results may differ materially from these forward-looking statements.Words such as anticipate,expect,intend,plan,believe,seek,estimate,variations of such words,and similar expressions are intended to identify such forward-looking statements,although not all forward-

4、looking statements contain these identifying words.These statements concern,and these risks and uncertainties include,among others,the nature,timing,and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees(c

5、ollectively,Regenerons Products)and product candidates being developed by Regeneron and/or its collaborators or licensees(collectively,Regenerons Product Candidates)and research and clinical programs now underway or planned,including without limitation EYLEA HD(aflibercept)Injection 8 mg,EYLEA(aflib

6、ercept)Injection,Dupixent(dupilumab)Injection,Libtayo(cemiplimab)Injection,Praluent(alirocumab)Injection,Kevzara(sarilumab)Injection,Evkeeza(evinacumab)Injection,Veopoz (pozelimab)Injection,Ordspono (odronextamab),itepekimab,fianlimab,garetosmab,linvoseltamab,Regenerons other oncology programs(inclu